1. Home
  2. CPBI vs NSPR Comparison

CPBI vs NSPR Comparison

Compare CPBI & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

N/A

Current Price

$17.49

Market Cap

72.8M

Sector

N/A

ML Signal

N/A

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.20

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPBI
NSPR
Founded
2023
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
72.1M
IPO Year
2023
2009

Fundamental Metrics

Financial Performance
Metric
CPBI
NSPR
Price
$17.49
$1.20
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
2.1K
55.0K
Earning Date
06-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.80
N/A
Revenue
N/A
$2,310,000.00
Revenue This Year
N/A
$57.98
Revenue Next Year
N/A
$95.41
P/E Ratio
$21.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.52
$1.12
52 Week High
$17.89
$2.93

Technical Indicators

Market Signals
Indicator
CPBI
NSPR
Relative Strength Index (RSI) 51.76 27.44
Support Level $17.37 N/A
Resistance Level $17.84 $2.47
Average True Range (ATR) 0.10 0.09
MACD -0.00 -0.00
Stochastic Oscillator 54.30 34.22

Price Performance

Historical Comparison
CPBI
NSPR

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

Share on Social Networks: